In-Vitro IBD Diagnostic Market Analysis

  • Report ID: 3414
  • Published Date: Oct 18, 2024
  • Report Format: PDF, PPT

In-Vitro IBD Diagnostic Market Analysis

The in-vitro inflammatory bowel disease (IBD) diagnostic market is segmented by product into assays/biomarkers and analyzers. Out of these, the assays/biomarkers segment is anticipated to hold the highest market share throughout the forecast period. The segment is also anticipated to grow with the highest CAGR of 5.6% during the forecast period. Further, on the basis of disease type, the market is segmented into ulcerative colitis and Crohn’s disease, out of which, the ulcerative colitis segment is anticipated to hold the highest market share and also grow with the highest CAGR of 5.7% during the forecast period. Based on disease stage, the market is segmented into mild, moderate, and severe, out of which, the severe segment is anticipated to hold the largest market revenue of USD 1225.89 Million by the end of 2028, up from a revenue of USD 823.27 Million in 2019. Further, on the basis of test type, the in-vitro inflammatory bowel disease (IBD) diagnostic market is segmented into blood tests, stool tests, antibody tests, and biopsy. Out of these segments, the blood tests segment is anticipated to hold the highest market share and also attain a market revenue of USD 931.51 Million by the end of 2028. On the basis of patient demography, the market is segmented into pediatric, adults, and geriatric, out of which, the adults segment is anticipated to hold the largest revenue of USD 1592.15 Million by the end of 2028. The market is also segmented on the basis of end-user into hospitals, clinics, diagnostic laboratories, and others. Out of these segments, the hospitals segment is projected to hold the highest market share and also attain a revenue of USD 1297.52 Million by the end of 2028. Moreover, on the basis of test method, the market is segmented into PETIA, ELISA, rapid, and others, out of which, the ELISA segment is expected to garner the highest in-vitro inflammatory bowel disease (IBD) diagnostic market revenue of USD 663.62 Million by the end of 2028, up from a revenue of USD 428.08 Million in 2019.

Our in-depth analysis of the global market includes the following segments:

Product

  • Assays/Biomarkers
  • Analyzers

Disease Type

  • Ulcerative Colitis
  • Crohn Disease

Disease Stage

  • Mild,
  • Moderate,
  • Severe

Test Type

  • Blood Tests,
  • Stool Tests,
  • Antibody Tests,
  • Biopsy

Patient Demography

  • Pediatric
  • Adults,
  • Geriatric

End-user

  • Hospitals
  • Clinics
  • Diagnostic Laboratories
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3414
  • Published Date: Oct 18, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of in-vitro IBD diagnostic is assessed at USD 1.91 billion.

In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market size was over USD 1.83 billion in 2023 and is projected to reach USD 3.58 billion by 2036, growing at around 5.3% CAGR during the forecast period i.e., between 2024-2036.

North America industry is estimated to account for largest revenue share of 44% by 2036

The major players in the market are are DiaSorin S.p.A., American Laboratory Products Company, Ltd. (d/b/a ALPCO Diagnostics), Quidel Corporation, CerTest Biotec, S.L., BUHLMANN Laboratories AG, and others.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample